TP53 and lung carcinoma: Interest is growing towards the possibility to define diverse NSCLC phenotypes through the identification of different co-mutational patterns [10,11], and a negative prognostic role has been described for TP53 and LKB1 (or STK11) in EGFR and KRAS mutant lung cancer, respectively [12,13,14,15,16,17].